


THIRD EDITION

Aulton's  
**Pharmaceutics**

THE DESIGN AND  
MANUFACTURE OF  
MEDICINES



Edited by  
Michael E. Aulton

CHURCHILL  
LIVINGSTONE  
ELSEVIER

Noven Pharmaceuticals, Inc.

**DOCKET**  
**A L A R M**

Find authenticated court documents without watermarks at [docketalarm.com](http://docketalarm.com).

**CHURCHILL  
LIVINGSTONE  
ELSEVIER**

An imprint of Elsevier Limited

© Harcourt Publishers Limited 2001  
© 2007, Elsevier Limited. All rights reserved.

The right of Michael E. Aulton to be identified as editor of this work has been asserted by him in accordance with the Copyright, Designs and Patents Act 1988

No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, without the prior permission of the Publishers. Permissions may be sought directly from Elsevier's Health Sciences Rights Department, 1600 John F. Kennedy Boulevard, Suite 1800, Philadelphia, PA 19103-2899, USA; phone: (+1) 215 239 3804; fax: (+1) 215 239 3805; e-mail: [healthpermissions@elsevier.com](mailto:healthpermissions@elsevier.com). You may also complete your request on-line via the Elsevier homepage ([www.elsevier.com](http://www.elsevier.com)), by selecting 'Support and Contact' and then 'Copyright and Permission'.

First edition 1988  
Second edition 2002  
Third edition 2007

ISBN-13: 9780443101083

International Edition ISBN-13: 9780443101076

**British Library Cataloguing in Publication Data**

A catalogue record for this book is available from the British Library

**Library of Congress Cataloging in Publication Data**

A catalog record for this book is available from the Library of Congress

**Note**

Knowledge and best practice in this field are constantly changing. As new research and experience broaden our knowledge, changes in practice, treatment and drug therapy may become necessary or appropriate. Readers are advised to check the most current information provided (i) on procedures featured or (ii) by the manufacturer of each product to be administered, to verify the recommended dose or formula, the method and duration of administration, and contraindications. It is the responsibility of the practitioner, relying on their own experience and knowledge of the patient, to make diagnoses, to determine dosages and the best treatment for each individual patient, and to take all appropriate safety precautions. To the fullest extent of the law, neither the Publisher nor the Editor assumes any liability for any injury and/or damage to persons or property arising out or related to any use of the material contained in this book.

**The Publisher**

**ELSEVIER** your source for books,  
journals and multimedia  
in the health sciences  
[www.elsevierhealth.com](http://www.elsevierhealth.com)

Working together to grow  
libraries in developing countries  
[www.elsevier.com](http://www.elsevier.com) | [www.bookaid.org](http://www.bookaid.org) | [www.sabre.org](http://www.sabre.org)  
**ELSEVIER** **BOOK AID** **Sabre Foundation**  
International

Printed in Hungary

The  
Publisher's  
policy is to use  
paper manufactured  
from sustainable forests

# Transdermal drug delivery

B. W. Barry

## CHAPTER CONTENTS

### Introduction 566

### Structure, function and topical treatment of human skin 566

Anatomy and physiology 567

Epidermis 568

Dermis 568

Subcutaneous tissue 568

Skin appendages 568

Functions of the skin 568

Mechanical function 568

Protective function 569

Rational approach to drug delivery to and via the skin 569

Surface treatment 569

Stratum corneum treatment 569

Skin appendage treatment 570

Viable epidermis and dermis treatment 571

Transcutaneous immunization 571

Systemic treatment via transdermal absorption 571

### Drug transport through the skin 571

Basic principles of diffusion through membranes 571

Diffusion process 571

Complex diffusional barriers 572

Skin transport 573

Routes of penetration 573

Sebum and surface material 573

Skin appendages 573

Epidermal route 573

General conclusions on drug transport through the skin 574

### Properties that influence transdermal delivery 574

Biological factors 575

Skin condition 575

Skin age 575

Blood flow 575

Regional skin sites 575

Skin metabolism 576

Species differences 576

Physicochemical factors 576

Skin hydration 576

Temperature and pH 576

Diffusion coefficient 577

Drug concentration 577

Partition coefficient 578

Molecular size and shape 578

Ideal molecular properties for drug penetration 579

### Drug permeation through skin 579

Stratum corneum rate controlling 579

Stratum corneum not rate controlling 579

Absorption from solution: skin a perfect sink 580

Absorption from suspensions: skin a perfect sink 580

### Methods for studying transdermal drug delivery 581

In vitro methods 581

Excised skin 581

Artificial membranes 582

Release methods without a rate-limiting membrane 582

In vivo methods 583

Histology 583

Surface loss 584

Microdialysis 584

Analysis of body tissues or fluids 584

Observation of a pharmacological or physiological response 585

Physical properties of the skin 585

Bioassays 585

### Maximizing the bioavailability of drugs applied to skin 585

Drug or prodrug selection 585

Chemical potential adjustment 586

Hydration 586

Ultrasound (phonophoresis) 586

Iontophoresis 586

Electroporation 586

Radiofrequency waves 586

Stratum corneum removal 587

Photomechanical wave 587

Microneedle array 587

Chemical penetration enhancers 587

Delivering the medicament to the diseased site is a problem with appendage treatment. For example, it is difficult to achieve a high antibiotic concentration in a sebaceous gland when, as in acne, a horny plug blocks the follicle. When delivered through the skin, the drug may not be sufficiently hydrophobic to partition from the water-rich viable epidermis and dermis into the sebum-filled gland.

#### **Viable epidermis and dermis treatment**

We can treat many diseases provided that the preparation efficiently delivers drug to the receptor. However, many potentially valuable drugs cannot be used topically as they do not readily cross the stratum corneum. Hence, investigators may use stratagems such as adding chemical penetration enhancers to diminish this layer's barrier function (discussed later in this chapter). Another approach develops prodrugs, which reach the biological receptor and release the pharmacologically active fragment. The efficacy of many topical steroids depends partly on molecular groups which promote percutaneous absorption but which may not enhance drug-receptor binding.

Drug examples include topical steroidal and non-steroidal antiinflammatory agents; corticosteroids may also be used in psoriasis. Antibiotics include those listed above. Anaesthetic drugs such as benzocaine, amethocaine and lidocaine reduce pain, and antipruritics and antihistamines alleviate itch, but they may cause sensitization. Topical 5-fluorouracil and methotrexate eradicate premalignant and some malignant skin tumours, and treat psoriasis. The psoralens (particularly in conjunction with ultraviolet light – PUVA therapy) mitigate psoriasis, and 5-aminolaevulinic acid (with visible light irradiation – photodynamic therapy) treats skin cancer.

#### **Transcutaneous immunization**

The skin has a highly effective immunological surveillance and effector system. A new therapy involves developing transcutaneous immunization via topical application of vaccine antigens. The process uses an adjuvant such as cholera toxin added to a vaccine antigen (e.g. diphtheria toxoid) to induce antibodies to the diphtheria toxoid. The adjuvant and antigen target Langerhans cells, potent antigen-presenting cells in the epidermis. Simple application of the vaccine formulation to the skin of experimental animals and human volunteers has produced positive responses.

#### **Systemic treatment via transdermal absorption**

Generally, in the past we have not used healthy skin as a drug route during systemic attacks on disease, with the noteworthy exceptions of nitroglycerin and antileptotics. The body absorbs drugs slowly and incompletely through

the stratum corneum and much of the preparation is lost by washing, by adherence to clothes and by shedding with stratum corneum scales. Other problems include marked variations in skin permeability with regard to subject, site, age and condition, which make control difficult. However, in recent years considerable scientific work has led to the route being used to treat several conditions by means of transdermal patches (discussed later in this chapter).

Figure 38.2 illustrates drug penetration routes and examples of treatments appropriate to various skin strata.

## **DRUG TRANSPORT THROUGH SKIN**

### **Basic principles of diffusion through membranes**

A useful way to study percutaneous absorption is to consider, first, how molecules penetrate inert (artificial) membranes and then move on to the special situation of skin transport. An understanding of the basic principles of permeation through membranes is also valuable in all other areas of biopharmaceutics – oral, buccal, rectal, nasal, lung, vaginal, uterine, injection or eye. The underlying mathematics are also relevant to dosage form design, particularly sustained- or controlled-release formulations and drug targeting.

#### **Diffusion process**

In passive diffusion, matter moves from one region of a system to another following random molecular motion. The basic hypothesis underlying the mathematical theory for isotropic materials (which have identical structural and diffusional properties in all directions) is that the rate of transfer of diffusing substance per unit area of a section is proportional to the concentration gradient measured normal to the section. This is expressed as Fick's First Law of Diffusion, Eqn 38.1:

$$J = -D \frac{\partial C}{\partial x} \quad (38.1)$$

where  $J$  is the rate of transfer per unit area of surface (the flux),  $C$  is the concentration of diffusing substance,  $x$  is the space coordinate measured normal to the section, and  $D$  is the diffusion coefficient. The negative sign indicates that the flux is in the direction of decreasing concentration, i.e. down the concentration gradient. In many situations  $D$  is constant but in more complex materials,  $D$  depends markedly on concentration; its dimensions are  $(\text{length})^2(\text{time})^{-1}$ , often specified as  $\text{cm}^2 \text{s}^{-1}$ .

Fick's First Law contains three variables,  $J$ ,  $C$  and  $x$ , of which  $J$  is additionally a multiple variable,  $dm/dt$ , where  $m$  is amount and  $t$  is time. We therefore usually employ Fick's Second Law, which reduces the number of variables by one. For the common experimental situation in

which diffusion is unidirectional, i.e. the concentration gradient is only along the  $x$ -axis, Eqn 38.2 expresses Fick's Second Law as:

$$\frac{\partial C}{\partial t} = D \frac{\partial^2 C}{\partial x^2} \quad (38.2)$$

Many experimental designs employ a membrane separating two compartments, with a concentration gradient operating during a run and 'sink' conditions (essentially zero concentration) prevailing in the receptor compartment. If we measure the cumulative mass of diffusant,  $m$ , which passes per unit area through the membrane as a function of time, we obtain the plot shown in Figure 38.3. At long times the plot approaches a straight line and from its slope we obtain the steady flux,  $dm/dt$  (Eqn 38.3):


$$\frac{dm}{dt} = \frac{DC_0 K}{h} \quad (38.3)$$

Here  $C_0$  is the constant concentration of drug in the donor solution,  $K$  is the partition coefficient of the solute between the membrane and the bathing solution, and  $h$  is the thickness of the membrane.

If a steady-state plot is extrapolated to the time axis, the intercept so obtained at  $m = 0$  is the lag time,  $L$ :

$$L = \frac{h^2}{6D} \quad (38.4)$$

From Eqn 38.4,  $D$  is estimated provided that the membrane thickness,  $h$ , is available. Knowing these parameters and  $C_0$ , and measuring  $dm/dt$ , Eqn 38.3 provides one way of assessing  $K$ . Eqn 38.3 shows why this permeation procedure may be referred to as a zero-order process. By analogy with chemical kinetic operations, Eqn 38.3 represents a zero-order process with a rate constant of  $DK/h$ .



**Fig. 38.3** The time course for absorption for the simple zero-order flux case obtained by plotting  $m$ , the cumulative amount of diffusant crossing unit area of membrane, as a function of time. Steady state is achieved when the plot becomes linear; extrapolation of the linear portion to the time axis yields the lag time  $L$ .

572

Sometimes with biological membranes (such as skin) we cannot separate the value of  $D$  from that of  $K$ . We then often employ a composite parameter, the permeability coefficient,  $P$ , where  $P = KD$  or  $P = KD/h$ . The latter definition is used when  $h$  is uncertain, e.g. diffusion through skin.

### Complex diffusional barriers

**Barriers in series** The treatment above deals only with the simple situation in which diffusion occurs in a single isotropic medium. However, skin is a heterogeneous multilayer tissue and in percutaneous absorption the concentration gradient develops over several strata. We can treat skin in terms of a laminate, each layer of which contributes a diffusional resistance,  $R$ , which is directly proportional to the layer thickness,  $h$ , and is indirectly proportional to the product of the layer diffusivity  $D$ , and the partition coefficient,  $K$ , with respect to the external phase. The total diffusional resistance of all the layers in a three-ply membrane such as skin (stratum corneum, viable epidermis and dermis) is given by the expression:

$$R_T = \frac{1}{P_T} = \frac{h_1}{D_1 K_1} + \frac{h_2}{D_2 K_2} + \frac{h_3}{D_3 K_3} \quad (38.5)$$

Here  $R_T$  is the total resistance to permeation,  $P_T$  is the thickness-weighted permeability coefficient, and the numerals refer to the separate skin layers.

If one segment has a much greater resistance than the other layers (e.g. the stratum corneum compared with the viable epidermis or dermis) then the single high-resistance phase determines the composite barrier properties. Then  $P_T = K_1 D_1 / h_1$ , where the subscript 1 refers to the resistant phase.

**Barriers in parallel** Shunts and pores, such as hair follicles and sweat glands, pierce human skin (see Fig. 38.1). Investigators often idealize this complex structure and consider the simple situation in which the diffusional medium consists of two or more diffusional pathways linked in parallel. Then the total diffusional flux per unit area of composite,  $J_T$  is the sum of the individual fluxes through the separate routes. Thus:

$$J_T = f_1 J_1 + f_2 J_2 \dots \quad (38.6)$$

where  $f_1, f_2$ , etc., denote the fractional areas for each diffusional route and  $J_1, J_2$ , etc., are the fluxes per unit area of each separate route. In general, for independent linear parallel pathways during steady state diffusion:

$$J_T = C_0 (f_1 P_1 + f_2 P_2 + \dots) \quad (38.7)$$

where  $P_1, P_2, \dots$  represent the thickness-weighted permeability coefficients.

If only one route allows diffusant to pass, i.e. the other routes are impervious, then the solution reduces to the

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.